Print Preview

Oxcarbazepine-8453

Test info

Test name:

Oxcarbazepine

Test number:

8453

Excellian order number:

LAB8453

Abbreviation:

OCX

Alternate names:

MHC
Oxcarbazepine metabolite
10-hydroxy metabolite
Trileptal

Useful for:

Therapeutic Drug Management

Specimen

Specimen type:

Serum

Collection container:

Red serum vial/tube - 5 mL

Volume:

2.0 mL

Minimum volume:

0.2 mL

Collection instructions:

Trough levels are the most reproducible

Processing instructions:

Allow sample to clot
Spin within two (2) hours of sample collection
Transfer serum to a Serum/plasma transfer vial/tube (MedTox), labelled as serum

Transport container:

Serum/plasma transfer vial/tube (MedTox)

Alternate specimen type:

Heparin plasma

Alternate collection container:

Dk green heparin (Li or Na), no gel

Alternate collection instructions:

Immediately following collection, mix sample by inverting 5 - 10 times to prevent clotting.

Alternate processing instructions:

Allow sample to clot
Spin within two (2) hours of sample collection
Transfer serum to a Serum/plasma transfer vial/tube (MedTox), labelled as the appropriate plasma type

Transport and stability:

Refrigerated (preferred)

Ambient - 3 days

Frozen (OK)

Reason for rejection:

Gel-barrier tubes are not recommended

Performance

Performing lab:

MedTox Laboratories (432): R-MX

Days set up:

Daily

TAT:

1 - 2 days

Method:

Immunoassay (IA)

Clinical and Interpretive info

Reference ranges:

10.0 - 35.0 µg/mL

Therapeutic efficacy has been demonstrated in patients with trough 10-hydroxy metabolite concentrations of 10.0 - 35.0 µg/mL

Results that require action (critical):

Not established

Clinical information:

Oxcarbazepine is an antiepileptic drug, indicated for use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults with epilepsy. It is used in adjunctive therapy in epileptic children between the ages of four and 16.

Billing

CPT codes:

80183

LOINC code:

Result 35331-8

Tracking

Date created:

11/15/2010

Revised date:

12/28/2023

Review date:

12/28/2023